Sei Investments Co. Lowers Stock Position in ACADIA Pharmaceuticals Inc. $ACAD

Sei Investments Co. cut its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) by 31.0% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 106,390 shares of the biopharmaceutical company’s stock after selling 47,740 shares during the quarter. Sei Investments Co. owned approximately 0.06% of ACADIA Pharmaceuticals worth $2,368,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC raised its position in shares of ACADIA Pharmaceuticals by 67.5% during the 4th quarter. Farther Finance Advisors LLC now owns 958 shares of the biopharmaceutical company’s stock valued at $26,000 after purchasing an additional 386 shares during the period. Meeder Asset Management Inc. bought a new position in ACADIA Pharmaceuticals in the 4th quarter worth $26,000. Transamerica Financial Advisors LLC increased its stake in ACADIA Pharmaceuticals by 304.5% in the 4th quarter. Transamerica Financial Advisors LLC now owns 1,335 shares of the biopharmaceutical company’s stock worth $36,000 after buying an additional 1,005 shares in the last quarter. Federated Hermes Inc. increased its stake in ACADIA Pharmaceuticals by 277.5% in the 4th quarter. Federated Hermes Inc. now owns 1,612 shares of the biopharmaceutical company’s stock worth $43,000 after buying an additional 1,185 shares in the last quarter. Finally, Leonteq Securities AG bought a new stake in ACADIA Pharmaceuticals during the fourth quarter valued at about $52,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the company. BMO Capital Markets boosted their price objective on ACADIA Pharmaceuticals from $34.00 to $36.00 and gave the company an “outperform” rating in a research report on Tuesday, July 21st. HC Wainwright reiterated a “buy” rating on shares of ACADIA Pharmaceuticals in a research report on Thursday. Stifel Nicolaus lifted their target price on ACADIA Pharmaceuticals from $24.00 to $25.00 and gave the company a “hold” rating in a research note on Tuesday, July 21st. Wall Street Zen raised ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Saturday. Finally, Royal Bank Of Canada upped their price target on ACADIA Pharmaceuticals from $36.00 to $37.00 and gave the stock an “outperform” rating in a research note on Wednesday. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $33.44.

Trending Headlines about ACADIA Pharmaceuticals

Here are the key news stories impacting ACADIA Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright raised its long-term earnings outlook. The firm increased its EPS forecasts to $0.56 for FY2026, $2.95 for FY2028, $3.28 for FY2029 and $3.42 for FY2030, while maintaining a Buy rating. The revisions imply confidence in ACADIA’s earnings growth trajectory. HC Wainwright earnings estimate revisions
• Positive Sentiment: Citizens JMP raised its ACADIA price target to $36. The higher target provides additional upside relative to the recent trading level and reinforces the bullish tone surrounding the stock. Citizens JMP raises ACADIA price target
• Positive Sentiment: Recent results exceeded expectations. ACADIA reported quarterly EPS of $0.18 versus a $0.07 consensus estimate and revenue of $308 million versus expectations of $296.55 million. Revenue increased 16.4% year over year, supporting the view that operating momentum is improving. ACADIA reaches new 52-week high after earnings beat
• Positive Sentiment: Rising earnings estimates are supporting the stock. Zacks highlighted ACADIA among healthcare companies with strong earnings momentum and said recent estimate revisions could support further near-term gains. Zacks ACADIA earnings estimate outlook
• Neutral Sentiment: A separate Zacks analysis compares ACADIA’s year-to-date performance with Amneal Pharmaceuticals and the broader medical sector, providing performance context rather than a new company-specific catalyst. ACADIA performance comparison
• Negative Sentiment: HC Wainwright trimmed its Q4 2026 EPS estimate slightly to $0.20 from $0.21 and used a Hold rating in one related note, signaling some caution around near-term results. HC Wainwright quarterly estimate update

ACADIA Pharmaceuticals Stock Up 2.7%

Shares of ACAD stock opened at $29.21 on Friday. The company’s fifty day simple moving average is $24.39 and its two-hundred day simple moving average is $23.27. ACADIA Pharmaceuticals Inc. has a 52 week low of $19.69 and a 52 week high of $29.48. The stock has a market cap of $5.03 billion, a P/E ratio of 13.16, a PEG ratio of 17.19 and a beta of 0.81.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported $0.18 earnings per share for the quarter, beating analysts’ consensus estimates of $0.07 by $0.11. ACADIA Pharmaceuticals had a return on equity of 9.03% and a net margin of 33.42%.The firm had revenue of $308.00 million during the quarter, compared to analyst estimates of $296.55 million. During the same quarter last year, the business posted $0.16 earnings per share. The business’s quarterly revenue was up 16.4% compared to the same quarter last year. On average, analysts anticipate that ACADIA Pharmaceuticals Inc. will post 0.57 EPS for the current fiscal year.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 5,401 shares of the firm’s stock in a transaction that occurred on Tuesday, May 26th. The stock was sold at an average price of $21.18, for a total transaction of $114,393.18. Following the completion of the transaction, the insider owned 24,509 shares in the company, valued at $519,100.62. This trade represents a 18.06% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, EVP Elizabeth H.Z. Thompson sold 16,558 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Thursday, July 30th. The stock was sold at an average price of $26.13, for a total value of $432,660.54. Following the completion of the sale, the executive vice president directly owned 18,994 shares in the company, valued at approximately $496,313.22. The trade was a 46.57% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 42,100 shares of company stock valued at $1,134,287. Insiders own 26.20% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of innovative therapies for central nervous system (CNS) disorders. Established in 1993 and headquartered in San Diego, California, ACADIA’s research centers concentrate on conditions with significant unmet medical needs, including Parkinson’s disease psychosis, Alzheimer’s disease psychosis, and schizophrenia. The company utilizes a range of scientific platforms, including selective receptor modulation and precision-targeted compounds, to advance its portfolio of small-molecule therapeutics.

The company’s flagship product, NUPLAZID® (pimavanserin), received U.S.